These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28471096)

  • 41. Emerging Agents of Substance Use/Misuse.
    Michienzi AE; Borek HA
    Emerg Med Clin North Am; 2022 May; 40(2):265-281. PubMed ID: 35461623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre.
    Hondebrink L; Nugteren-van Lonkhuyzen JJ; Van Der Gouwe D; Brunt TM
    Drug Alcohol Depend; 2015 Feb; 147():109-15. PubMed ID: 25541244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Psychoactive Substances and Trends of Abuse.
    Rivera JV; Vance EG; Rushton WF; Arnold JK
    Crit Care Nurs Q; 2017; 40(4):374-382. PubMed ID: 28834859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of new psychoactive substances and prescription drugs in the Belgian driving under the influence of drugs population.
    Wille SMR; Richeval C; Nachon-Phanithavong M; Gaulier JM; Di Fazio V; Humbert L; Samyn N; Allorge D
    Drug Test Anal; 2018 Mar; 10(3):539-547. PubMed ID: 28640970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.
    Anderson C; Morrell C; Marchevsky D
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25948854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differences in combinations and concentrations of drugs of abuse in fatal intoxication and driving under the influence cases.
    Edvardsen HE; Tverborgvik T; Frost J; Rogde S; Morild I; Waal H; Clausen T; Slørdal L; Vindenes V
    Forensic Sci Int; 2017 Dec; 281():127-133. PubMed ID: 29128652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine.
    Huppertz LM; Moosmann B; Auwärter V
    Drug Test Anal; 2018 Jan; 10(1):206-211. PubMed ID: 28378533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
    Zawilska JB
    Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Psychoactive Substances consumption and their monito- ring during Covid-19 pandemic.
    Di Trana A; La Maida N
    Clin Ter; 2021 Jul; 172(4):271-272. PubMed ID: 34247209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted and non-targeted drug screening in whole blood by UHPLC-TOF-MS with data-independent acquisition.
    Mollerup CB; Dalsgaard PW; Mardal M; Linnet K
    Drug Test Anal; 2017 Jul; 9(7):1052-1061. PubMed ID: 27750404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Classical and novel psychoactive substances: rethinking drug misuse from an evolutionary psychiatric perspective.
    St John-Smith P; McQueen D; Edwards L; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):394-401. PubMed ID: 23881888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey.
    Simonato P; Corazza O; Santonastaso P; Corkery J; Deluca P; Davey Z; Blaszko U; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):324-31. PubMed ID: 23881880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans.
    Nugteren-van Lonkhuyzen JJ; van Riel AJ; Brunt TM; Hondebrink L
    Drug Alcohol Depend; 2015 Dec; 157():18-27. PubMed ID: 26530501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intoxication with new psychoactive substances: drug unknown, but complications are still treatable].
    Boersma MN; Nugteren-van Lonkhuyzen JJ; van Maarseveen EM; Kaasjager HAH; van Riel AJHP; Dekker D
    Ned Tijdschr Geneeskd; 2017; 161():D1368. PubMed ID: 28659208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicokinetics of NPS: Update 2017.
    Meyer MR
    Handb Exp Pharmacol; 2018; 252():441-459. PubMed ID: 29476337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.
    Valeriani G; Corazza O; Bersani FS; Melcore C; Metastasio A; Bersani G; Schifano F
    Hum Psychopharmacol; 2015 Jul; 30(4):249-54. PubMed ID: 26216558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.